New Oral PPD Treatment Zuranolone Will Soon Hit the Market as Zurzuvae
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Update on Postpartum Depression Documentary: More Than Blue
We are looking to include two additional women who are early on in the postpartum period (under one year) and recovering from postpartum depression.
ADHD as a Risk Factor for Postpartum Depression and Anxiety
ADHD is an important risk factor for both depression and anxiety disorders in the postpartum period and should be considered in the post-pregnancy maternal care.
Planned Initiatives from the Department of Health and Human Services Focus on Maternal Mental Health
 Some good news from our colleagues at the Maternal Mental Health Leadership Alliance (MMHLA)... The United States Department of Health and Human Services (HHS) is planning to launch significant initiatives addressing the maternal mental [...]
Zuranolone: A novel postpartum depression treatment, with lingering questions
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
A New Study Investigates the Impact of a Drospirenone-Only Contraceptive Pill On Postpartum Mood
Postpartum women taking a drospirenone-only contraceptive pill experienced a decrease in depressive symptoms.
Using Predictive Modeling to Examine IV Ketamine and Esketamine for the Prevention of Postpartum Depression
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
FDA Approves Zuranolone for the Treatment of Postpartum Depression
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market?
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Postpartum Psychosis: Identifying Population-Level Risk FactorsÂ
Women with medical, psychiatric, and obstetric risk factors should be closely followed within pregnancy and the postpartum.